DB01590

GPTKB entity

Statements (44)
Predicate Object
gptkbp:instanceOf gptkb:drug
gptkbp:approvalYear 2010 (US)
gptkbp:ATCCode B01AE07
gptkbp:bioavailability 6.5%
gptkbp:brand gptkb:Pradaxa
gptkbp:CASNumber 211914-51-1
gptkbp:contraindication active pathological bleeding
mechanical prosthetic heart valve
gptkbp:developer gptkb:Boehringer_Ingelheim
gptkbp:eliminationHalfLife 12-17 hours
gptkbp:excretion renal
gptkbp:hasBoxedWarning increased risk of thrombotic events after premature discontinuation
risk of spinal/epidural hematoma
gptkbp:hasDrugBankCategory gptkb:anticoagulant
gptkbp:hasInChIKey XXRSQQURJIBGAE-UHFFFAOYSA-N
gptkbp:hasMolecularFormula C34H41N7O5
gptkbp:hasPharmacodynamics inhibits both free and clot-bound thrombin
gptkbp:hasPharmacokinetics rapid absorption, low bioavailability, renal excretion
gptkbp:hasSMILES CC(C)N1C(=O)NC(C(=O)N(C2CC2)C3=CC=CC=C3)C1=O
gptkbp:hasUNII 2ZC8355BTE
https://www.w3.org/2000/01/rdf-schema#label DB01590
gptkbp:indication treatment and prevention of deep vein thrombosis
treatment and prevention of pulmonary embolism
prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation
gptkbp:legalStatus prescription only
patent expired in US (2021)
gptkbp:mechanismOfAction direct thrombin inhibitor
gptkbp:metabolism hepatic
gptkbp:molecularWeight 627.74
gptkbp:name gptkb:Dabigatran
gptkbp:pregnancyCategory C (US)
gptkbp:proteinBinding 35%
gptkbp:PubChem_CID gptkb:CHEMBL1201197
D08167
135565729
gptkbp:routeOfAdministration oral
gptkbp:sideEffect bleeding
gastrointestinal upset
gptkbp:status true
gptkbp:synonym gptkb:BIBR_1048
gptkb:Dabigatran_etexilate
gptkbp:target gptkb:thrombin
gptkbp:bfsParent gptkb:everolimus
gptkbp:bfsLayer 6